Skyhawk Therapeutics Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration in Phase 1 Huntington’s Disease Patient Trial
Press Releases
Skyhawk Therapeutics  
December 9, 2024

Skyhawk Therapeutics Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration in Phase 1 Huntington’s Disease Patient Trial

Australian Human Research Ethics Committees approves SKY-0515 treatment for up to 12 weeks in the company's ongoing Phase 1 trial in patients with Huntington's Disease

avatar profile Olean Times Herald

Olean Times Herald


Local & Social